Pioneering diagnostics

Strong ties with research institutions

Innovation has been at the heart of bioMérieux’s strategy since the Company’s beginnings. This mindset of being open to new possibilities is developed through international, multidisciplinary public and private-sector collaborations with academic research organizations, the medical and scientific community, and cutting-edge biotech companies.

 

  • In October 2016, bioMérieux, BIOASTER (the French accelerator of microbiology technology innovation), the College of Industrial Physics and Chemistry of the city of Paris (ESPCI), GSK, Lyon Civil Hospitals and Sanofi joined their expertise to fight against sepsis within a research program named REALISM (REAnimation Low Immune Status Markers). Hosted by BIOASTER and the joint research laboratory bioMérieux-HCL, at the Édouard Herriot Hospital in Lyon, this project aims to improve the management for patients presenting a high risk of sepsis. When the project reaches completion in late 2018, the results will allow industrial partners to develop diagnostic and therapeutic solutions for sepsis.
     
  • In May 2016, bioMérieux inaugurated the new facilities of this joint research laboratory.The collaboration contract, begun in 2002, was also renewed for five years, and the alliance grew with the addition of Claude Bernard University Lyon 1 to the partnership. 
  • In May 2017, the research program ANTOINE (biomArkers to differeNtiate bacTerial frOm vIral iNfEctions) was launched by the bioMérieux-HCL joint research laboratory at the Lyon Sud Hospital. This project, which contributes to the fight against antimicrobial resistance, focuses on the diagnosis of severe bacterial infections in children presenting to the Emergency Department.
  • As a partner of the Pasteur Institute since 2010, bioMérieux is taking part in a project to combat artemisinin resistance in the treatment of malaria, as well as improving the diagnostis of Chagas’ disease, within the scope of the Global and Tropical Infectious Diseases (GTID) program.
  • In November 2017, bioMérieux entered into a research partnership in Brazil with the São Paulo Research Foundation (FAPESP), the Institute of Tropical Medicine and the Faculty of Medicine of the University of São Paulo to combat the complications associated with dengue, chikungunya and Zika infections within the scope of the ARBOBIOS project. The research program will involve at least 2,000 patients and a research team of 20 scientists.